agitation in alzheimers disease epidemiology forecast
Agitation in Alzheimer's Disease Insights and Trends
- In 2025, the total number of diagnosed cases of agitation in Alzheimer's disease in the 7MM was around 10 million. Among the 7MM countries, the US accounted for the highest number of diagnosed prevalent cases of Alzheimer’s disease, contributing around 50%, while the UK reported the lowest number of cases in 2025.
- Increasing recognition of agitation in Alzheimer’s disease across clinical settings is being supported by wider use of standardized behavioral assessment tools and greater reliance on caregiver-reported observations, improving identification and differentiation from other neuropsychiatric symptoms.
- Agitation in Alzheimer’s disease accounted for approximately 5 million diagnosed cases in the US, highlighting a substantial and often under-recognized neuropsychiatric burden within the Alzheimer’s disease population.
- In EU4 and the UK, approximately ~3 million total diagnosed prevalent cases of agitation in Alzheimer’s disease were reported in 2025, reflecting a significant regional burden, with cases expected to grow further by 2036.
- In 2025, EU4 and the UK recorded higher diagnosed prevalent cases of agitation in Alzheimer’s disease among females (~2 million) compared to males (~900,000), with this gender distribution expected to remain consistent through 2026–2036, primarily due to longer female life expectancy, post-menopausal hormonal changes reducing neuroprotection, higher overall disease prevalence in women, and greater likelihood of diagnosis and survival duration.
- According to DelveInsight’s analysts, there were ~4 million diagnosed prevalent cases of Alzheimer's disease and ~2.5 million diagnosed with agitation in Japan in 2025, reflecting the high patient burden of this disease.
- From an epidemiological and diagnostic perspective, agitation in Alzheimer’s disease is characterized by significant heterogeneity in symptom presentation and the absence of standardized diagnostic biomarkers, leading to reliance on clinical assessment and caregiver-reported outcomes. This variability contributes to inconsistencies in case identification, underreporting, and differences in prevalence estimates across populations, highlighting a critical gap in accurate disease burden assessment.
Agitation in Alzheimer's Disease Epidemiology Forecast
- 2025 Agitation in Alzheimer's Disease Diagnosed Prevalent Cases in the 7MM: ~10 million
- Agitation in Alzheimer's Disease Growth Rate (2026–2036) in the 7MM: 2.8% CAGR
DelveInsight's ‘Agitation in Alzheimer's disease – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of Agitation in Alzheimer’s disease, historical and forecasted epidemiology trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
The Agitation in Alzheimer’s disease epidemiology report provides a comprehensive analysis of prevalent cases, capturing the number of diagnosed patients across the 7MM. It includes detailed segmentation by age and gender, along with regional distribution. The report evaluates historical and forecasted prevalence trends (2026–2036), highlighting variations in disease occurrence and diagnosis patterns, and offering insights into the evolving burden of newly diagnosed Agitation in Alzheimer’s disease cases.
Geography Covered
- North America: The US
- Europe: Germany, France, Italy, Spain and the UK
- Asia-Pacific: Japan
|
Study Period |
2022–2036 |
|
Historical Year |
2022–2025 |
|
Forecast Period |
2026–2036 |
|
Base Year |
2025 |
|
Geographies Covered |
|
|
Agitation in Alzheimer's Epidemiology CAGR (Forecast period) |
2.8% (2026-2036) |
|
Agitation in Alzheimer's Disease Epidemiology Segmentation Analysis |
Patient Burden Assesment
|
|
Analysis |
|
Agitation in Alzheimer's Disease Understanding
Agitation in Alzheimer's Disease Overview and Diagnosis
Agitation in Alzheimer’s disease is a common neuropsychiatric manifestation characterized by emotional distress, excessive motor activity, irritability, and, at times, aggressive behaviors, arising from progressive neurodegeneration affecting cognitive and behavioral regulation. The presentation varies across disease stages but often includes restlessness, verbal or physical aggression, mood lability, and resistance to care, significantly impacting patient quality of life and caregiver burden.
Diagnosis is primarily clinical, based on detailed patient history, caregiver reports, and standardized assessment scales, as no definitive biomarkers are currently established for agitation in Alzheimer’s disease. Clinicians rely on tools such as the Neuropsychiatric Inventory (NPI), Cohen-Mansfield Agitation Inventory (CMAI), and clinical interviews to quantify symptom severity, frequency, and impact on daily functioning. Evaluation focuses on identifying underlying and potentially reversible triggers, including environmental stressors (e.g., changes in routine, overstimulation), unmet needs (such as pain, hunger, or discomfort), and comorbid medical or psychiatric conditions like infections, depression, or sleep disturbances.
Further details are provided in the report.
Agitation in Alzheimer's Disease Epidemiology
Key Findings from Agitation in Alzheimer's Disease Epidemiological Analysis and Forecast
- The total number of diagnosed cases of Alzheimer’s disease in the 7MM is ~16 million in 2025.
- According to DelveInsight’s estimates, in the United States, diagnosed cases of agitation in Alzheimer ’s disease are predominantly made up of females, accounting for ~ 3 million cases in 2025.
- In Japan, the age-specific diagnosed cases of agitation in Alzheimer ’s disease is 3% (~64,000 cases) for ages <65 years, having the least number of cases, 14% for 65–74 years, 32% for =85 years and 51% (~1 million) for 75–84 years, contributing the highest number of cases.
- Diagnosed cases of agitation in Alzheimer’s disease in Germany were predominantly female, with a gender distribution of about 30% male and 70% female.
Industry Experts and Physician Views for Agitation in Alzheimer's Disease
To keep up with agitation in Alzheimer’s disease epidemiology trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the agitation in Alzheimer’s disease epidemiology, prevalence trends, regional distribution, patient demographics, diagnostic rates, and real-world disease burden patterns in agitation in Alzheimer’s disease, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.
DelveInsight’s analysts connected with 10+ KOLs to gather insights at country level. Centers such as the The University of Texas Health Science Center, Gerontological Society of America, German Center for Neurodegenerative Diseases, University Hospital of Toulouse etc. were contacted.
Their opinion helps understand and validate agitation in Alzheimer’s disease epidemiological trends, highlight key gaps in diagnosis and disease burden, provide deeper epidemiological context, and support strategic decisions for patient identification and disease monitoring in agitation in Alzheimer’s disease.
|
Region |
Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) |
|
United States |
“Agitation in Alzheimer’s disease and related dementias is increasingly recognized as a significant neurobehavioral burden with substantial caregiver impact. Growing evidence suggests that agitation is closely linked to disease severity and reflects underlying frontal lobe dysfunction, which may amplify behavioral responses to coexisting psychopathology and environmental triggers, positioning it as a distinct frontal lobe-driven syndrome within the broader Alzheimer’s disease spectrum.” |
|
Germany |
“Emerging evidence highlights a neurobiological basis for agitation in Alzheimer’s disease, implicating early tau-related changes in the locus coeruleus and dysregulation of affective executive networks. These findings suggest compensatory noradrenergic overactivity and emotion regulation deficits may differentially influence agitation risk and severity, warranting further investigation.” |
Scope of the Report
- The report covers a segment of key epidemiological highlights, an executive summary, and a descriptive overview of Agitation in Alzheimer’s disease, including its causes, risk factors, and factors influencing disease occurrence.
- Comprehensive insights are provided into prevalence trends and forecasts, along with the future growth potential of diagnosis rates and evolving patterns of disease detection across the 7MM.
- Additionally, the report includes detailed segmentation of prevalent cases by histological subtype, age, gender, and region, offering a granular view of the epidemiological landscape.
- A thorough assessment of historical and forecasted prevalence data, along with underlying assumptions and methodology, is included, providing a clear understanding of disease burden across the 7MM.
- The report provides strategic insights by highlighting trends in prevalence, diagnostic gaps, and regional variations, supported by expert opinions and epidemiological analysis to better understand and project the Agitation in Alzheimer’s disease disease burden.
Report Insights
- Agitation in Alzheimer’s disease prevalence forecast, epidemiological burden, segmentation, trends, and opportunity assessment.
Report Key Strengths
- Epidemiology-based (EPI - based) bottom-up forecasting
- Artificial Intelligence (AI) - enabled epidemiology research report
- 11-year forecast
- Agitation in Alzheimer’s disease epidemiological outlook (North America, Europe, Asia-Pacific)
- Agitation in Alzheimer’s disease Burden trends (by geography)
Report Assessment
- Agitation in Alzheimer’s disease Diagnostic Trends
- Agitation in Alzheimer’s disease Epidemiological Gaps
- Agitation in Alzheimer’s disease Development Trends
- Agitation in Alzheimer’s disease Emerging Research Focus
- Agitation in Alzheimer’s disease Disease Burden Attractiveness
- Agitation in Alzheimer’s disease Qualitative Epidemiological Insights
FAQs
- What was the Agitation in Alzheimer’s disease prevalent patient population and distribution (%) in 2025, and how will it evolve by 2036? What factors are driving these trends?
- What are the anticipated variations in prevalence and diagnosis rates across different geographies?
- What will be the future diagnosis and epidemiological trends of Agitation in Alzheimer’s disease?
- What are the disease risks, burden, and key epidemiological gaps in Agitation in Alzheimer’s disease? What are the growth opportunities based on the patient population across the 7MM?
- How will changes in prevalence and diagnosis impact the overall epidemiological landscape?
- What are the current diagnosis practices and epidemiology trends of Agitation in Alzheimer’s disease in the US, Europe, UK, and Japan?
Reasons to Buy
- The report will help in developing strategies by understanding the latest trends and changing epidemiology of Agitation in Alzheimer’s disease.
- Bottom-up forecasting builds from the prevalent patient population, delivering a robust, data-driven epidemiological approach.
- Insights on patient burden/prevalence, evolution in diagnosis, and factors contributing to changes in disease epidemiology during the forecast years.
- Understand the epidemiological opportunities across varying geographies and growth potential over the coming years.
- Identifying key trends in disease prevalence will help anticipate shifts in the epidemiological landscape.
- Detailed analysis and segmentation of prevalent cases to provide visibility around high-burden patient groups.
- To understand KOLs’ perspectives on diagnosis challenges and gaps in disease identification.
- Detailed insights on epidemiological unmet needs to support improved disease tracking and diagnosis strategies.
- This Artificial Intelligence (AI)-enabled report summarizes complex epidemiological datasets into clear, actionable insights for stakeholders, investors, and healthcare providers.
